Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- PRAX
- Price
- 29.74
- Stock movement up
- +1.27 (4.46%)
- Company name
- Praxis Precision Medicines Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 554.29M
- Ent value
- 419.23M
- Price/Sales
- 345.35
- Price/Book
- 1.45
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -41.19%
- 3 year return
- -44.08%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
PRAX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 345.35 |
| Price to Book | 1.45 |
| EV to Sales | 261.20 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 18.64M |
| EPS (TTM) | -8.00 |
| FCF per share (TTM) | -5.26 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 1.60M |
| Gross profit (TTM) | 1.27M |
| Operating income (TTM) | -164.01M |
| Net income (TTM) | -151.02M |
| EPS (TTM) | -8.00 |
| EPS (1y forward) | -11.73 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 79.44% |
| Operating margin (TTM) | -10219.00% |
| Profit margin (TTM) | -9409.22% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 168.65M |
| Net receivables | 0.00 |
| Total current assets | 360.05M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 416.26M |
| Accounts payable | 15.01M |
| Short/Current long term debt | 1.66M |
| Total current liabilities | 32.86M |
| Total liabilities | 33.59M |
| Shareholder's equity | 382.67M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -99.50M |
| Capital expenditures (TTM) | 50.00K |
| Free cash flow (TTM) | -99.28M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -39.46% |
| Return on Assets | -36.28% |
| Return on Invested Capital | -39.34% |
| Cash Return on Invested Capital | -25.86% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 28.12 |
| Daily high | 29.94 |
| Daily low | 28.12 |
| Daily Volume | 416K |
| All-time high | 903.00 |
| 1y analyst estimate | 150.67 |
| Beta | 2.69 |
| EPS (TTM) | -8.00 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 12 May 2025 |
Downside potential
Loading...
Downside potential data
| PRAX | S&P500 | |
| Current price drop from All-time high | -96.71% | -12.89% |
| Highest price drop | -98.67% | -56.47% |
| Date of highest drop | 30 Mar 2023 | 9 Mar 2009 |
| Avg drop from high | -80.65% | -11.07% |
| Avg time to new high | 56 days | 12 days |
| Max time to new high | 1071 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
554.29M
Marketcap category
Small-cap
Description
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Employees
82
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page